The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Open accessAbstract
Background & Aims Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. Methods We examined at-risk individuals (NAFLD cohort, n = 2,566; 226 with HCC; and a replication cohort of 427 German patients with NAFLD) and the general population (UK Biobank [UKBB] cohort, n = 364,048; 202 with HCC). Variants in PNPLA3-TM6SF2-GCKR-MBOAT7 were combined in a hepatic fat PRS (PRS-HFC), and then adjusted for HSD17B13 (PRS-5). Results In the NAFLD cohort, the adjusted impact of genetic risk variants on HCC was proportional to the predisposition to fatty liver ( p = 0.002) with some heterogeneity in the effect. PRS predicted HCC more robustly than single variants ( p < 10 -13 ). The association between PRS and HCC was mainly mediated through severe fibrosis, but was independent of fibrosis in clinically relevant subgroups, and was also observed in those without severe fibrosis ( p < 0.05). In the UKBB cohort, PRS predicted HCC independently of classical risk factors and cirrhosis ( p < 10 -7 ). In the NAFLD cohort, we identified high PRS cut-offs (≥0.532/0.495 for PRS-HFC/PRS-5) that in the UKBB cohort detected HCC with ~90% specificity but limited sensitivity; PRS predicted HCC both in individuals with ( p < 10 -5 ) and without cirrhosis ( p < 0.05). Conclusions Our results are consistent with a causal relationship between hepatic fat and HCC. PRS improved the accuracy of HCC detection and may help stratify HCC risk in individuals with dysmetabolism, including those without severe liver fibrosis. Further studies are needed to validate our findings. Lay summary By analyzing variations in genes that contribute to fatty liver disease, we developed two risk scores to help predict liver cancer in individuals with obesity-related metabolic complications. These risk scores can be easily tested in the clinic. We showed that the risk scores helped to identify the risk of liver cancer both in high-risk individuals and in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Comprehensive polygenic risk scores are superior to PNPLA3 and TM6SF2 alone for risk prediction of progressive MASLD, especially in individuals with metabolic triggers, and the bene fi ts of their use over clinical risk factors alone becomes more evident for long-term prediction. 196,206,207”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another model incorporated genetic variants in a risk score that predicted HCC independently of classical risk factors, but the AUROC when used alone was only 0.65. 206”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018) · BMJ · doi:10.1136/bmj.k601 · Cited by 4,404
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–385 of 385
Miyano, T., & Mikkaichi, T. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040057 · Cited by 1
Alyousifi, Y., Raut, C., Chen, V. L., Oliveri, A., Chen, Y., & Speliotes, E. K. (2026) · Liver International · doi:10.1111/liv.70410 · Cited by 1
Ji, X., Wang, Y.-W., Li, L.-X., Yang, H.-H., Ma, Z., Wang, C., Zhao, Y.-H., Ding, Y., & Xia, Y. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70372 · Cited by 1
Blood Pressure Trajectories in Young Adulthood and Midlife Steatotic Liver Disease
Chen, Y., Zhao, L., Zheng, Y., Carr, J. J., Gao, T., Terry, J. G., Qu, Y., Ning, H., Zhang, X., Wilkins, J. T., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26319 · Cited by 1
Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD
Messer, E. K., Fischer, J., Herta, T., Boehlig, A., Matz‐Soja, M., Tuennemann-Tarr, A., Gaul, S., Laufs, U., & Berg, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349666 · Cited by 1
The future of blood-based biomarkers in liver cancer
Singal, A. G., Saborowski, A. L., Parikh, N. D., & Banales, J. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.040 · Cited by 1
Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target
Noor, S., Tian, Y., & Su, W. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1912237 · Cited by 1
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 4
Mei, Q., Shou, D., Quan, Y., Cheng, J., Pan, P., Chen, H., Huang, H., Li, Y., Xia, Y., & Zhou, Y. (2022) · Science of Advanced Materials · doi:10.1166/sam.2022.4317 · Cited by 1
Genetic data not yet a “game-changer” for predicting individualised hepatocellular carcinoma risk
Innes, H. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.015 · Cited by 1
Jacobs, M., Morris, E., Haleem, Z. M., Mandato, N., Marlow, N. M., & Revere, L. (2023) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s401474 · Cited by 1
Hepatitis Viruses: Hepatocellular Carcinoma
Lee, D., Yang, J. D., Chaiteerakij, R., & Roberts, L. R. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_34-1 · Cited by 1
Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology
Ekanayaka, S. P. N., Luke, N. V., Thilakarathne, S., Dassanayake, A. S., Gunetilleke, M. B., Niriella, M. A., & Siriwardana, R. C. (2024) · Indian Journal of Gastroenterology · doi:10.1007/s12664-024-01636-9 · Cited by 1
Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up
Yu, M., Wu, W., Lin, C., Liu, C., Peng, W., Huang, P., Huang, Y., Hu, J., Chang, H., & Liou, J. (2024) · Hepatology Research · doi:10.1111/hepr.14101 · Cited by 1
Is PAaM Truly the Answer for Precise Hepatocellular Carcinoma Risk Stratification?
Zheng, Y., & Shan, D. (2025) · Gastroenterology · doi:10.1053/j.gastro.2024.11.038 · Cited by 1
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease patients
Truong, E., & Noureddin, M. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.63 · Cited by 1
Editorial: the polygenic risk of cirrhosis development
Armandi, A., & Schattenberg, J. M. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16298 · Cited by 1
Reply to: “Lack of hepatic autophagy promotes severity of liver injury but not steatosis”
Baselli, G., Romeo, S., & Valenti, L. V. C. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.026 · Cited by 1
Sohn, W., & Paik, Y. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0411 · Cited by 1
Paolini, E., Longo, M., Meroni, M., Podini, P., Maggioni, M., Quattrini, A., Fracanzani, A. L., & Dongiovanni, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592717 · Cited by 1
Longo, M., Paolini, E., Meroni, M., Ripolone, M., Napoli, L., Gentile, F., Cespiati, A., Maggioni, M., Alisi, A., Miele, L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.03.597155 · Cited by 1
Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver DiseasePreprint
Baselli, G., Pelusi, S., Ciociola, E., Dongiovanni, P., Maggioni, M., Bianco, C., Tavaglione, F., Cespiati, A., Mancina, R. M., Malvestiti, F., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3806074
Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease
Kim, D. Y., & Park, J. Y. (2021) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.093
Epidemiologia e storia naturale della NAFLD, una malattia sistemica
Salvatore Petta, G. P. (2021) · il Diabete · doi:10.30682/ildia2102a
MIra, J., & Paredes, Y. Á. (2007) · Revista Real Academia Galega de Ciencias
Healthy Sleep Patterns, Genetic Susceptibility, and Incident of Cirrhosis and Liver CancerPreprint
Wang, H., Qin, S., Zhang, S., Shen, Q., Zhu, Y., Tian, J., Chang, J., & Zhong, R. (2022) · Research Square · doi:10.21203/rs.3.rs-2280143/v1
Samarasinghe, S. M., Hewage, A. S., Siriwardena, R., Tennekoon, K. H., Niriella, M. A., Silva, S. D., & Viswakula, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2336549/v1
Genetic Variants Determine Treatment Response in Autoimmune Hepatitis
Zandanell, S., Balcar, L., Semmler, G., Schirmer, A., Leitner, I., Rosenstatter, L., Niederseer, D., Sotlar, K., Schneider, A.-M., Straßer, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030540
Association between TLR4 Polymorphism and NAFLD Susceptibility
赵, 守. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371508
Artificial intelligence in precision medicine and liver disease monitoring
Su, T., & Kao, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99136-0.00016-7
Kim, K., & Park, J. Y. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-501
Han, T., Li, C., Wang, B., Xu, Y., & Xu, B. (2023) · Research Square · doi:10.21203/rs.3.rs-3649517/v1
Nischalke, H. D., Schmalz, F., Fischer, J., Möller, C., Matz‐Soja, M., Krämer, B., Langhans, B., Nattermann, J., Berg, T., Strassburg, C. P., et al. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010002
GENETIC MECHANISMS OF HEPATOCELLULAR CARCINOMA: LITERATURE REVIEW
Amirkulova, A., Derbissalina, G., Shanazarov, N. A., & Bekbergenova, Z. (2024) · Oncologia i radiologia Kazakhstana · doi:10.52532/2521-6414-2024-1-71-46-50
Jia, Y., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Yi, L., & Liao, X. (2023) · Figshare · doi:10.6084/m9.figshare.24416199
Future directions for fatty liver disease
Bartolomeo, A. D., & George, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00016-9
Chun, H. S., Lee, M., & Kim, T. H. (2024) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2024.12.3.184
Clayton‐Chubb, D., Majeed, A., Kemp, W. W., Yu, C., Lange, P. W., Fitzpatrick, J. A., Woods, R. L., Tonkin, A., Chan, A. T., Nelson, M. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13081977
Shi, Z., Feng, K., Yang, X., Gao, Y., & Wang, X. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.079
Liao, Y., Yan, X., Tai, J., Deng, Y., Yu, C., Chen, X., Zhang, P., Wang, S., Zhou, M., Chen, X., et al. (2025) · Liver International · doi:10.1111/liv.70355
Precision prevention of liver cancer based on risk factors
Chen, J. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100595
Zhou, Y., Zhou, D., Chen, S., Yang, C., Wu, S., Wang, X., Lu, Y., Lu, Y., Zhou, M., Wu, S., et al. (2025) · Genes & Nutrition · doi:10.1186/s12263-025-00779-4
Yang, R., Shen, C., Jia, Y., Yao, Y., Zhou, Y., Cheng, Y., Cheng, Y., Zeng, R., Wan, Z., Zhao, Q., et al. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000949 · Cited by 2
Qadri, S. U., Haas, J. T., Jäntti, S. E., Porthan, K., Juuti, A., Penttilä, A. K., Arola, J., Vartiainen, E., Dirinck, E. L., Vonghia, L., et al. (2025) · medRxiv · doi:10.1101/2025.11.18.25340381
Zhang, S., Yan, Y., Gu, Y., Wu, H., Zhang, Q., Liu, L., Borné, Y., Qi, L., Huang, T., Chen, Y., et al. (2025) · Food & Function · doi:10.1039/d5fo04464b
Jia, Y., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Lei, Y., & Liao, X. (2024) · Figshare · doi:10.6084/m9.figshare.26629825
Jia, Y., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Lei, Y., & Liao, X. (2023) · Figshare · doi:10.6084/m9.figshare.24416294
Jia, Y., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Lei, Y., & Liao, X. (2024) · Figshare · doi:10.6084/m9.figshare.26629822
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Chen, Y., Zhao, L., Mezzacappa, C., Steffen, L. M., Carr, J. J., Gao, T., Terry, J. G., Qu, Y., Bae, S., Taddei, T. H., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.019
Feng, T.-Y., Hsu, K., Liao, G., & Hong, Z. (2026) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_166_25
Arriaga-González, F. G., Castañeda-Córdova, F. D. J., Díaz‐Muñoz, M., Hoare, M., Adams, D., Robles‐Espinoza, C. D., & Molina‐Aguilar, C. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02332-7 · Cited by 1
Hepatocellular Carcinoma in the Setting of Metabolic Dysfunction Associated Steatotic Liver Disease
Su, A., Clark, J. M., & Kim, A. K. (2026) · Current Hepatology Reports · doi:10.1007/s11901-025-00707-5
Very low-density lipoprotein and the human health
Bharadwaj, A., Taneja, M., Dubey, S., & Saxena, A. (2026) · World Journal of Experimental Medicine · doi:10.5493/wjem.v16.i1.117024
Chotiprasidhi, P., Umpierre, V. P. G., Nartey, Y. A., Miller, H. B., Gefre, A. F., Sato‐Espinoza, K., O'Brien, D., Ma, J., Awuku, Y. A., Agyei-Nkansah, A. A., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00446
Valenti, L. V. C., & Malvestiti, F. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.031
Polygenic Risk Scores in Chronic Hepatitis B–Related HCC: Promise Beyond Conventional Models?
Khan, T., Ahmed, M., Saad, M., Saqib, H. W., & Moazzam, M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70388
Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology
Pirola, C. J., & Sookoian, S. C. (2026) · Med · doi:10.1016/j.medj.2026.101131
Lee, M. K., Stepanova, M., Estep, M., You, Y.-L., Liu, X.-R., de Avila, L., Lam, B., Yu, M., & Younossi, Z. M. (2026) · Liver International · doi:10.1111/liv.70675 · Cited by 1
Wu, N., Xiong, X., Wang, X. Y., Wei, S., Shi, X., Chen, Y., Zhou, W., Wang, J., Zhang, L., Liu, B., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11107-2
Possible correlations between infertility and adverse metabolic profile: a case-control study
Aquino, C. I., Vercellino, N., Elisabetta, F., Ferrante, D., Rigamonti, C., Rosalba, M., Pirisi, M., Valentino, R., Bellan, M., & Daniela, S. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115250
Toshida, K., Takeishi, K., Itoh, S., Kurihara, T., Motomura, T., Ishikawa, T., Iwasaki, H., Mita, J., Nakayama, Y., Tomiyama, T., et al. (2026) · Liver International · doi:10.1111/liv.70770
Gatzios, A., Stinckens, M., Verhoeven, A., Rombaut, M., Win, D. D., Heymans, A., Loosen, A., Goethem, F. V., Kock, J. D., Rodrigues, R. M., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124587
Li, D. R., Zhou, Z., Liang, G., Zeng, D., Zhou, Z., Li, X., Qiu, T., Zhang, Y., Lin, J., Chen, Y., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70583
He, X.-L., Yang, R.-X., & Fan, J.-G. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.32
Ye, C., Zhang, Z. K., Ding, Y., Yu, Y., Zhang, S., Pan, J., Nie, S., Li, S., Zhang, L. R., Lu, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71113
Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology
Crespo, J., Alonso‐Peña, M., Jiménez-González, C., Cayon, L., & Iruzubieta, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081145
Jones, E., Eppler, N., Ahamed, F., & Zhang, Y. (2026) · Livers · doi:10.3390/livers6040074 · Cited by 2
Han, Z., Song, H., Wang, C., Li, Q., Ye, Y., Liu, W., Pang, G., Sun, W., Zhu, X., Wang, S., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20370-4
Guariglia, M., Caviglia, G. P., Gaia, S., Rosso, C., Rolle, E., Saba, F., Dileo, E., Silvestri, G. M., Armandi, A., CARUCCI, P., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1931260
Fan, W.-J., Wu, Y.-M., Liu, X.-Y., Zhang, C.-A., Hu, C., Wang, B.-B., & Ding, H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.08.008
Ajmera, V. H., Schwantes-An, T.-H. L., Díaz, L. A., Zaborenko, C. J., Yates, K. P., Chalasani, N., & Loomba, R. S. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.033
Huai, Q., Li, X., Wang, H., & Yin, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.09.004
Lee, J., Hoon, J., Cho, H. S., Yang, H., Byun, M. Y., Cho, S. K., Yang, S. W., Bae, S. H., Kim, S. U., Yu, S. J., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70762
Li, Y., Peng, Z., Zhang, J., Cao, H., & Zhang, J. (2026) · iScience · doi:10.1016/j.isci.2026.117035
Gawrieh, S., Tan, J., Guo, X., Schwantes-An, T.-H. L., Abreu, M., Zaborenko, C. J., Gómez, E. V., Schwimmer, J. B., Rotter, J. I., & Chalasani, N. (2026) · Liver International · doi:10.1111/liv.70907
Beyond fibrosis: the molecular roadmap from MASLD to hepatocellular carcinoma
Nevi, L., Altomare, A., Gallo, P., Taffon, C., Musarra, T., Baiocchini, A., & Carotti, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1933386
Shetty, P. B., Choi, N., Duong, H. T., Kanwal, F., Khaderi, S. A., Singal, A. G., Asrani, S. K., Luster, M., Alsarraj, A., Rao, A., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72375
Qin, Z., Juramt, D., Chen, Y., Li, Y., Wei, J., Yang, H., Chen, L., & Qiu, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1946657
Arash, E. H., Groeger, M., Grenert, J. P., Wittmann, T., Raffaı̈, R. L., Maher, J. J., & Willenbring, H. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118116
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Kang, T. W., & Song, B. G. (2026) · Korean Journal of Radiology · doi:10.3348/kjr.2026.0168
Li, C., Li, M., Wang, B., & Ji, G. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2737572
Metadata
- Authors
- Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., Borroni, V., D’Ambrosio, R., Spagnuolo, R., Alisi, A., Federico, A., Bugianesi, E., Petta, S., Miele, L., Vespasiani-Gentilucci, U., Anstee, Q. M., Stickel, F., Hampe, J., Fischer, J., Berg, T., Fracanzani, A. L., Soardo, G., Reeves, H., Prati, D., Romeo, S., & Valenti, L.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Sahlgrenska University Hospital (SE)
- University of Milan (IT)
- University of Udine (IT)
- Agostino Gemelli University Polyclinic (IT)
- Bambino Gesù Children's Hospital (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Palermo (IT)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University Hospital Zurich (CH)
- University Hospital Carl Gustav Carus (DE)
- University Hospital Leipzig (DE)
- Corresponding author
- Romeo, Stefano
- Valenti, Luca
- ORCID
- Bianco, Cristiana
- Jamialahmadi, Oveis
- Pelusi, Serena
- Baselli, Guido
- Dongiovanni, Paola
- Maier, Silvia
- Liguori, Antonio
- Meroni, Marica
- Borroni, Vittorio
- D’Ambrosio, Roberta
- Spagnuolo, Rocco
- Alisi, Anna
- Federico, Alessandro
- Bugianesi, Elisabetta
- Petta, Salvatore
- Miele, Luca
- Anstee, Quentin M.
- Stickel, Felix
- Hampe, Jochen
- Fischer, Janett
- Berg, Thomas
- Fracanzani, Anna Ludovica
- Soardo, Giorgio
- Reeves, Helen
- Prati, Daniele
- Romeo, Stefano
- Valenti, Luca
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 74
- Issue
- 4
- Pages
- 775-782
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC7987554
- OpenAlex
- W3106622583
- Cited by
- 385
- References
- 37
- Citations by year
- 2026: 60 · 2025: 60 · 2024: 68 · 2023: 80 · 2022: 64 · 2021: 52
- FWCI
- 35.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Institutional Research Information System (University of Udine) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_169196)
- Marianne and Marcus Wallenberg Foundation (KAW 2017.0203)
- Knut och Alice Wallenbergs Stiftelse
- Swiss Foundation for Alcohol Research
- AbbVie
- Akebia Therapeutics
- Amgen
- Novo Nordisk
- Novo Nordisk Fonden (DIA 2017-205, 9321-430)
- Hjärt-Lungfonden (20120533)
- European Research Council
- Seventh Framework Programme
- Diabetesförbundet
- Sanofi
- Pfizer
- Celgene
- Vetenskapsrådet (2016-01527)
- European Commission
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (RC100017A)
- Associazione Italiana per la Ricerca sul Cancro (16888)
- Ministero della Salute (RF-2016-02364358)
- Cancer Research UK (C18342/A23390, C9380/A18084, C9380/A26813)
- Gilead Sciences
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, polygenic risk score, HCC risk stratification, hepatic steatosis, liver fibrosis, PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13, genetic susceptibility, liver cirrhosis, HCC detection, UK Biobank
- MeSH terms
- Mediation Analysis, Cross-Sectional Studies, Europe, Female, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Factors, Risk Assessment, Genetic Predisposition to Disease, Multifactorial Inheritance, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
